Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11562262 | 0.91 | KDM4E (0.44) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL4891782 | 0.85 | KDM4E (0.43) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL3319314 | 0.80 | L3MBTL1 (0.52) | TTRTP53MAPTALDH1A1NPSR1 | |
| SCHEMBL1780791 | 0.76 | SMN1; SMN2 (0.41) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL7412860 | 0.76 | KDM4E (0.42) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL12844283 | 0.74 | SMN1; SMN2 (0.42) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL4353356 | 0.73 | ALDH1A1 (0.46) | KDM4ENPC1RAB9ATTRGAA | |
| SCHEMBL23978357 | 0.72 | ALDH1A1 (0.41) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL3320936 | 0.72 | SMN1; SMN2 (0.41) | KDM4ENPC1RAB9ATTRTP53 | |
| SCHEMBL4664165 | 0.71 | BCHE (0.45) | KDM4EPOLBALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166548-A1 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | SANOFI (FR) | 2017-06-15 | — | — | US | disclosed |
| US-9440941-B2 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | SANOFI (FR) | 2016-09-13 | — | — | US | disclosed |
| US-20160016928-A1 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | SANOFI (FR) | 2016-01-21 | — | — | US | disclosed |
| EP-1165500-A1 | AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES,TNF-ALPHA,AND AGGRECANASE | Du Pont Pharmaceuticals Company (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000059874-A1 | NOVEL AMIDE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016928-A1 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | RYR2, RYR1, CACNA1E | KDM4E 2622/4885NPC1 343/4885RAB9A 917/4885 |
| US-20170166548-A1 | Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals | RYR2, RYR1, CACNA1E | KDM4E 2616/4885NPC1 336/4885RAB9A 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.